April 3, 2020

CMA Encourages Ethical COVID-19 Vaccine Research

Philadelphia, PA- April 3, 2020—The Catholic Medical Association announced today its opposition of the use of cells from aborted babies being used to develop a vaccine for Covid-19.

“We need to ensure vaccinating as many people as possible. To achieve this goal, we must ensure the availability of an equally efficacious vaccine be produced that would not dissuade a pro-life individual or person of faith from receiving a life-saving medication due to immoral methods of production,” said CMA President, Dr. Michael Parker.

Dr. Parker, speaking on behalf of Catholic Medical Association, which supports vaccines and vaccine research—especially in this time of global pandemic—urges scientists to use moral methods in their work.

“We should not have to use vaccines from aborted stem cell lines when other morally acceptable alternatives exist, said Dr. Parker.

Despite the urgent need for a vaccine to protect the world against Covid-19, several companies are unfortunately exploiting innocent children whose lives were lost by abortion to conduct research.

Back in June, Catholic Medical Association applauded the life affirming action of The United States Department of Health and Human Services to stop funding research using the bodies of babies who were aborted. 

“The use of fetal tissue from an elective abortion for research is not only the ultimate cannibalization of human life, but unnecessary regardless of how promising the research,” said Dr. Marie Hilliard, Co-Chair of CMA’s Ethics Committee.

The CMA noted the policy clearly indicates the growing public awareness that from the moment of conception the unborn child is a human being who has the right to be respected and protected. This truth must remain recognized as the world works to contain Covid-19. 

“As we think of the countless lives a vaccine will save, we must not forget our duty to protect the value and dignity of all lives—inside and outside of the womb,” added Dr. Parker.  

For more information or to contact the research companies visit the links below:
Janssen
Johnson &Johnson